ArticleOpen forum infectious diseases2022
Noninvasive Testing and Surrogate Markers in Invasive Fungal Diseases.
Article in Open forum infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Blood Culture-Negative Endocarditis: A Scientific Statement From the American Heart Association:Journal of the American Heart Association · 2025Guideline
- Therapeutic Failure in Invasive Fungal Infections: Beyond Antifungal Resistance-A Narrative Review.Journal of fungi (Basel, Switzerland) · 2026Review
- Diagnostic Failure in Invasive Fungal Infections: Causes, Clinical Consequences, and Mitigation Strategies.Journal of fungi (Basel, Switzerland) · 2026Review
- Global perspective on gaps in fungal diagnostics in low-resource settings: WHO landscape analysis and research priorities for invasive fungal diseases.The Lancet. Microbe · 2026Review
- The Emergence of a Fatal Rash in a Renal Transplant Patient.Open forum infectious diseases · 2026Article
- Review
- Management of mould pneumonia in resource-limited settings in Asia: A Delphi-based consensus statement by the Asia Fungal Working Group.Medical mycology · 2025Article
- Invasive Gastrointestinal Mucormycosis Presenting as Neutropenic Enterocolitis: A Case Report.The American journal of case reports · 2025Article
- What Is the Prognostic Significance of Culture-Documented Breakthrough Invasive Pulmonary Aspergillosis in Patients with Hematological Malignancies? A Propensity Score-Adjusted Analysis.Journal of fungi (Basel, Switzerland) · 2025Article
- Breaking the mould: challenging the status quo of clinical trial response definitions for invasive fungal diseases-a debate.The Journal of antimicrobial chemotherapy · 2024Article
- Insights into invasive fungal infection diagnostic and treatment capacities in tertiary care centres of Germany.JAC-antimicrobial resistance · 2024Article
- Treatment ofJAC-antimicrobial resistance · 2024Article
- The added value of (1,3)-β-D-glucan for the diagnosis of Invasive Candidiasis in ICU patients: a prospective cohort study.Infection · 2024Article
- Novel Diagnostic Methods for Infective Endocarditis.International journal of molecular sciences · 2024Review
- Outbreaks of Fungal Infections in Hospitals: Epidemiology, Detection, and Management.Journal of fungi (Basel, Switzerland) · 2023Review
- Fungal Endocarditis: Pathophysiology, Epidemiology, Clinical Presentation, Diagnosis, and Management.Clinical microbiology reviews · 2023Review
- Review
- Diagnosis and Management of Severe Water-Related Skin and Soft Tissue Sepsis: A Summative Review of the Literature.Diagnostics (Basel, Switzerland) · 2023Review
- Invasive Fungal Infections after Liver Transplantation.Journal of clinical medicine · 2023Review
- Diagnosis and Treatment of Pulmonary Coccidioidomycosis and Paracoccidioidomycosis.Journal of fungi (Basel, Switzerland) · 2023Review
Corrections and comments
- Erratum issued
Authors and funding
16 authors.
Funding
Abstract
Invasive fungal infections continue to increase as at-risk populations expand. The high associated morbidity and mortality with fungal diseases mandate the continued investigation of novel antifungal agents and diagnostic strategies that include surrogate biomarkers. Biologic markers of disease are useful prognostic indicators during clinical care, and their use in place of traditional survival end points may allow for more rapid conduct of clinical trials requiring fewer participants, decreased trial expense, and limited need for long-term follow-up. A number of fungal biomarkers have been developed and extensively evaluated in prospective clinical trials and small series. We examine the evidence for these surrogate biomarkers in this review and provide recommendations for clinicians and regulatory authorities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.